Streamlining Aimovig Prior Authorization for Cardiology-Integrated Workflows

While Aimovig (erenumab), a CGRP receptor antagonist, is primarily prescribed for preventive migraine therapy, its prior authorization often arises within health systems that also manage high-volume cardiology services. Klivira provides a unified platform to streamline specialty drug PAs, including Aimovig, across integrated care settings.

Managing prior authorizations for specialty drugs presents significant administrative burdens for health systems. For revenue cycle directors and PA coordinators, optimizing workflows for diverse medications, even those outside a department's primary prescribing domain, is essential. Klivira helps health systems, including those with robust cardiology departments, efficiently manage the complexities of specialty drug prior authorization.

The Interplay of Aimovig PA and Cardiology Operations

Aimovig, indicated for chronic and episodic migraine, is typically prescribed by neurology or primary care. However, in integrated health systems, cardiology departments often share centralized revenue cycle operations or treat patients with complex comorbidities. This necessitates a comprehensive PA strategy that can efficiently process authorizations for all specialty drugs, ensuring seamless patient care and optimized financial outcomes, even when the medication is not directly cardiac-related.

Aimovig Prior Authorization: Core Requirements

Aimovig (erenumab) is a CGRP receptor antagonist used for migraine prevention. Prior authorization for Aimovig commonly involves demonstrating medical necessity based on the patient's diagnosis of chronic or episodic migraine. Payers frequently require documentation of prior step therapy, typically through a trial of generic preventive medications, before approving CGRP inhibitors.

Common Documentation for Aimovig PA Approval

Confirmed diagnosis of chronic or episodic migraine, often with frequency and severity documentation.
Detailed history of failed trials with at least two or more prior preventive migraine therapies.
Documentation of patient adherence to previous treatment regimens.
Absence of contraindications for Aimovig.
Physician attestation of medical necessity and expected benefits.

Optimizing Specialty Drug PA in Cardiology-Rich Environments

Cardiology departments manage a high volume of specialty drug PAs for medications like PCSK9 inhibitors, sacubitril/valsartan, and SGLT2 inhibitors for heart failure. Klivira's platform extends this capability to all specialty drugs within a health system. By automating the identification of payer-specific requirements and routing requests to the appropriate channels—whether payer-direct, PBMs, or specialty benefit managers—Klivira streamlines the PA process for medications like Aimovig, alongside the specific needs of cardiology.

Klivira's Platform for Comprehensive PA Management

Klivira integrates with EMRs to extract clinical data, applies payer-specific policy logic, and automates the submission and tracking of prior authorizations for a broad spectrum of specialty drugs. This reduces manual effort, accelerates approval times, and minimizes denials across all departments. For health systems with cardiology services, Klivira ensures that both high-volume cardiac PAs and other specialty drug PAs like Aimovig are managed with efficiency and precision.

Frequently asked questions

Do cardiologists typically prescribe Aimovig?

No, Aimovig (erenumab) is a CGRP receptor antagonist primarily prescribed by neurologists or primary care physicians for the preventive treatment of migraine. While cardiologists may manage patients with cardiovascular comorbidities who also have migraines, they typically do not prescribe Aimovig.

What are the primary indications for Aimovig?

Aimovig is indicated for the preventive treatment of migraine in adults. This includes both chronic migraine and episodic migraine, as defined by specific diagnostic criteria. It functions as a calcitonin gene-related peptide (CGRP) receptor antagonist.

How does Klivira handle prior authorizations for specialty drugs like Aimovig?

Klivira automates the prior authorization process for a wide range of specialty drugs, including Aimovig. Our platform integrates with EMRs, applies payer-specific policy rules, and automatically submits requests to the relevant payer portals or specialty benefit managers, streamlining the workflow and reducing administrative burden.

What are common denial reasons for Aimovig prior authorizations?

Common denial reasons for Aimovig prior authorizations include insufficient documentation of a confirmed migraine diagnosis, failure to demonstrate an adequate trial and failure of prior generic preventive migraine therapies (step therapy requirements), or incomplete clinical information supporting medical necessity.

How does Klivira integrate with EMRs for specialty drug PA?

Klivira leverages bi-directional EMR integration, often via SMART on FHIR, to automatically extract necessary patient data for prior authorization requests. This eliminates manual data entry, ensures accuracy, and seamlessly returns PA status updates directly into the patient's chart, optimizing the workflow for all specialties, including those managing specialty drugs like Aimovig.